People treated for aggressive melanoma now have a concrete reason to watch a single experimental combination closely. In a ...

For most of the past three years, Jim Cramer kept his distance from Moderna, treating the biotech stock with skepticism bordering on avoidance. The Cambridge, Massachusetts, company had become ...

From space to healthcare and artificial intelligence, what could the next 250 years of the United States look like?

Moderna ( MRNA +10.01%) stock jumped about 10% on Thursday to $79.76 -- a fresh high for the year and the latest leg of a run ...

Moderna surges 33.5% after the company outlines plans to expand its mRNA platform beyond vaccines into oncology, autoimmune diseases and cell therapies.

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...

University of Medicine and Health Sciences has shown success in targeting neuroblastoma. The research represents an ...